Lancet Diabetes Endocrinol

Oxytocin in response to MDMA provocation test in patients with arginine vasopressin deficiency (central diabetes insipidus): a single-centre, case-control study with nested, randomised, double-blind, placebo-controlled crossover trial

This double-blind, placebo-controlled study (n=30) explores oxytocin deficiency in patients with arginine vasopressin deficiency (central diabetes insipidus), using MDMA as a biochemical and psychoactive provocation test. The participants included patients with vasopressin deficiency and healthy controls, who were given either MDMA or placebo in a randomised order over two sessions.

Published

July 1, 2023

Journal

Lancet Diabetes Endocrinol

Authors

Atila, C., Christ-Crain, M., Liechti, M. E., Holze, F., Murugesu, R., Phd, R., Hutter, N., Sailer, C. O., Heinrichs, M., Rommers, N., Varghese, N., Eckert, A.